humanized anti-HM1.24 monoclonal antibody

Humanized anti-HM1.24 monoclonal antibody (AHM) is an engineered IgG1-κ monoclonal antibody targeting HM1.24 (also known as CD317 or BST2), a membrane protein highly expressed on multiple myeloma (MM) cells and plasma cells. AHM exerts its therapeutic effect primarily through antibody-dependent cellular cytotoxicity (ADCC) in the presence of human effector cells, leading to selective lysis of MM cells, but lacks complement-dependent cytotoxicity (CDC) activity. Preclinical studies demonstrated antitumor activity in cell lines and xenograft models, and a phase I/II clinical trial in relapsed/refractory multiple myeloma patients showed modest response rates with manageable adverse effects. Defucosylated or Fc-engineered variants (such as YB-AHM and XmAb5592) have been developed to enhance ADCC. The mechanism exploits the HM1.24 antigen's overexpression on malignant plasma cells, with AHM binding to the antigen and engaging immune effector mechanisms to kill target cells. The main indication is multiple myeloma, especially in relapsed or refractory settings[1][2][3][4][6].

Other names

anti-HM1.24anti-HM-1.24anti-HM 1.24humanized anti-HM1.24 mAbanti-BST2anti-BST-2anti-BST 2anti-CD317anti-CD-317anti-CD 317